Tyrosine kinase inhibitors in CML: better outcomes, lower hospital cost

  • PDF / 169,808 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 74 Downloads / 187 Views

DOWNLOAD

REPORT

1173-5503/20/0866-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

PharmacoEconomics & Outcomes News 14 Nov 2020 No. 866

1

Data Loading...

Recommend Documents
Resistance to Tyrosine Kinase Inhibitors

167 28 3MB

Bcr-abl-tyrosine-kinase-inhibitors/hydroxycarbamide/methylprednisolone

169 78 167KB

MRI in suspected scaphoid fracture: better outcomes, lower cost

169 35 163KB

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

220 89 484KB

Tenecteplase for ischaemic stroke: better outcomes, lower cost

163 80 163KB

Tyrosine Kinase

167 111 92MB

Amniotic membrane in dry-eye disease: better outcomes at lower cost

148 8 163KB

Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment fo

176 75 763KB

Anaplastic lymphoma kinase inhibitors

169 97 167KB

Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis

176 71 1MB

Therapeutic Kinase Inhibitors

109 69 5MB

Receptor Kinase Inhibitors Target NSCLC

201 43 81KB